Form 4: UroGen Pharma Exec Sells Shares Under 10b5-1 Plan

UroGen Pharma's Chief Medical Officer, Mark Schoenberg, sold 10,000 ordinary shares for $300,000 under a pre-arranged trading plan.

Summary

• Mark Schoenberg, Chief Medical Officer of UroGen Pharma Ltd. (URGN), reported a transaction involving the sale of 10,000 ordinary shares.
• The transaction occurred on May 8, 2026, and was executed under a Rule 10b5-1(c) trading plan adopted on August 15, 2025.
• The shares were sold at a weighted average price of $30.00, with individual sales ranging from $30.00 to $30.05.
• The total value of the transaction was approximately $300,000.
• Following this transaction, Schoenberg beneficially owns 134,985 ordinary shares directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While insider selling can be a negative signal, the transaction was conducted under a pre-arranged 10b5-1 plan, mitigating concerns about opportunistic selling.

Positives

• The sale was conducted under a pre-established 10b5-1 trading plan, indicating adherence to a structured and compliant selling strategy.
• The transaction was executed at a specific price range, providing transparency for the sale.
• Mark Schoenberg continues to hold a significant number of shares (134,985) directly, suggesting ongoing commitment to the company.

Negatives

• A significant number of shares (10,000) were sold by a key executive, which could be perceived negatively by the market.
• The sale represents a reduction in the executive's direct beneficial ownership.

Risks

• Potential for negative market perception due to insider selling, even if conducted under a 10b5-1 plan.
• The specific reasons for the sale under the 10b5-1 plan are not detailed, leaving room for speculation.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, as it solely reports a past transaction.

Management Comments

• The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

Industry Context

StockSavvy.ai notes that Form 4 filings are routine disclosures for insider transactions. While sales by executives can sometimes signal a lack of confidence, sales executed under a Rule 10b5-1 plan are pre-scheduled and designed to avoid insider trading concerns, making them less indicative of immediate negative sentiment compared to unscheduled sales.

Stakeholder Impact

• Shareholders: May interpret the sale as a negative signal, although the 10b5-1 plan mitigates this concern. Continued direct ownership by the executive provides some reassurance.
• Employees: Similar to shareholders, the impact is likely minimal due to the structured nature of the sale.
• Management: The transaction reflects adherence to compliance protocols for executive stock sales.

Next Steps

• The reporting person will provide detailed pricing information upon request from the Issuer, security holders, or the SEC staff.

Key Dates

Keywords

UroGen Pharma, URGN, Form 4, Insider Trading, 10b5-1 Plan, Mark Schoenberg, Share Sale, Beneficial Ownership, Chief Medical Officer